RPI ID: 2024-023-301
Innovation Summary: This technology provides systems and methods for assessing fracture risk by measuring circulating levels of F2-isoprostanes, which are biomarkers of oxidative stress. The approach integrates biochemical analysis with predictive modeling to evaluate bone fragility. It enables early identification of individuals at elevated risk for fractures, particularly in aging or metabolically compromised populations. The system is designed for clinical and research use, supporting personalized risk assessment.
Challenges / Opportunities: Current fracture risk assessments rely heavily on bone density measurements, which may not capture underlying biochemical contributors to bone weakness. This invention addresses the need for more sensitive and biologically relevant indicators. It opens opportunities for earlier intervention and improved patient outcomes. The method also supports biomarker-driven strategies in osteoporosis and metabolic bone disease management.
Key Benefits / Advantages: ✔ Uses oxidative stress biomarkers for fracture risk prediction ✔ Enables early and personalized risk assessment ✔ Complements traditional bone density testing ✔ Applicable to aging and metabolically at-risk populations
Applications: • Clinical diagnostics and risk screening for bone health
Keywords: Fracture risk, F2-isoprostanes, oxidative stress, bone biomarkers, osteoporosis diagnostics
Intellectual Property: WO2025117940A1 (Application PCT/US2024/058059), Published December 2, 2024